Abstract
Clinical trials of chimeric antigen receptor (CAR)-modified T cells have shown promise in hematologic malignancies. However, in solid tumors, the clinical responses have been less impressive. It is important to determine how to further improve the clinical effects of CAR-modified T cells. In this review, we focus on recent clinical trials and analyze the factors that determine clinical responses, including the following: 1) the composition of the CAR; 2) the preparation of CAR-modified T Cells; 3) the clinical treatment schedule; 4) the patient characteristics. We also propose future Strategies that must be investigated before the technology can be used in a wider range of clinical applications.
Keywords: Adoptive cell therapy, chimeric antigen receptor, T cell, cancer immunotherapy, cancer gene therapy, clinical trial, T cell receptor, single chain fragment variable
Current Gene Therapy
Title:Strategies to Improve the Clinical Performance of Chimeric Antigen Receptor-Modified T Cells for Cancer
Volume: 13 Issue: 1
Author(s): Qing Zhang, Huizhong Li, Jie Yang, Liantao Li, Baofu Zhang, Jia Li and Junnian Zheng
Affiliation:
Keywords: Adoptive cell therapy, chimeric antigen receptor, T cell, cancer immunotherapy, cancer gene therapy, clinical trial, T cell receptor, single chain fragment variable
Abstract: Clinical trials of chimeric antigen receptor (CAR)-modified T cells have shown promise in hematologic malignancies. However, in solid tumors, the clinical responses have been less impressive. It is important to determine how to further improve the clinical effects of CAR-modified T cells. In this review, we focus on recent clinical trials and analyze the factors that determine clinical responses, including the following: 1) the composition of the CAR; 2) the preparation of CAR-modified T Cells; 3) the clinical treatment schedule; 4) the patient characteristics. We also propose future Strategies that must be investigated before the technology can be used in a wider range of clinical applications.
Export Options
About this article
Cite this article as:
Zhang Qing, Li Huizhong, Yang Jie, Li Liantao, Zhang Baofu, Li Jia and Zheng Junnian, Strategies to Improve the Clinical Performance of Chimeric Antigen Receptor-Modified T Cells for Cancer, Current Gene Therapy 2013; 13 (1) . https://dx.doi.org/10.2174/1566523211313010007
DOI https://dx.doi.org/10.2174/1566523211313010007 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index To Volume 8
Current Pharmaceutical Design The Epigenetics of Breast Carcinogenesis and Metastasis
Current Genomics Edtorial [Hot topic: Glucocorticoids from Chemistry to Clinics (Executive Editor: Fortunato Vesce)]
Current Pharmaceutical Design Implications of Melatonin Therapy in Irritable Bowel Syndrome: A Systematic Review
Current Pharmaceutical Design Radiosensitizing Potential of Epigenetic Anticancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Molecular Targets from VHL Studies into the Oxygen-Sensing Pathway
Current Cancer Drug Targets Multiscale Mapping of AIDS in U.S. Countries vs Anti-HIV Drugs Activity with Complex Networks and Information Indices
Current Bioinformatics In-silico & In-vitro Identification of Structure-Activity Relationship Pattern of Serpentine & Gallic Acid Targeting PI3Kγ as Potential Anticancer Target
Current Cancer Drug Targets Effects of BCR-ABL Inhibitors on Anti-Tumor Immunity
Current Medicinal Chemistry Acute Pain Management in Hospitalized Children
Reviews on Recent Clinical Trials Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Anethole Inhibits the Proliferation of Human Prostate Cancer Cells via Induction of Cell Cycle Arrest and Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Advanced Vectors for Gene Delivery
Current Drug Therapy The Effect of Quercetin on Doxorubicin Cytotoxicity in Human Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Novel Findings of Anti-cancer Property of Propofol
Anti-Cancer Agents in Medicinal Chemistry The Flavin-Containing Monoooxygenases (FMOs): Genetic Variation and its Consequences for the Metabolism of Therapeutic Drugs
Current Pharmacogenomics Editorial [Hot Topic: Why Apoptosis in Pediatric Disorders?]
Current Pediatric Reviews Gas1 is a Pleiotropic Regulator of Cellular Functions: from Embryonic Development to Molecular Actions in Cancer Gene Therapy
Mini-Reviews in Medicinal Chemistry The AcrB Efflux Pump: Conformational Cycling and Peristalsis Lead to Multidrug Resistance
Current Drug Targets Homology Modelling of Human E1 Ubiquitin Activating Enzyme
Letters in Drug Design & Discovery